Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced that Northside Hospital Cancer Institute (NHCI) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.
Northside Hospital has been offering cancer care services in Georgia since 1978, and in that time has grown into one of the largest and most respected providers of cancer care services in the Southeast. The hospital has one of the largest community-based oncology research networks in the nation, and is one of a few community cancer programs in the country offering Phase I-IV clinical trials. Northside also leads Georgia’s National Cancer Institute Oncology Research Program (GA NCORP), and is one of 15 U.S. biorepositories for the National Institute of Health Cancer Moonshot Biobank℠ Program.
“NHCI continually stays on the leading edge of cancer research, and joining Caris’ POA with other leading cancer centers further supports that vision,” said Guilherme Cantuaria, M.D., Ph.D, chairman of Northside Hospital Cancer Institute and principal investigator of GA NCORP. “Caris’ POA provides access to innovative research collaborations that allow us to continue to provide patients in communities across Georgia access to state-of-the-art cancer treatment opportunities through personalized cancer care that combines the best treatments with the latest procedures and technology, specifically tailored to each patient’s cancer.”
In 2014, Northside was awarded a grant by the National Cancer Institute (NCI), as a member of the NCI Community Oncology Research Program (NCORP), to implement a new cancer research program that aims to reach more Georgians in their own cities and towns, ensuring they have access to the best possible patient care. The GA NCORP grant was renewed in 2019 for another six years.
“We are thrilled to welcome Northside Hospital Cancer Institute to the POA network,” said Chadi Nabhan, M.D., MBA, FACP, chairman of the Caris Precision Oncology Alliance. “As one of the nation's largest cancer programs, and the statewide leader of the National Cancer Institute Oncology Research Program (NCORP), NHCI’s mission and vision aligns with the POA’s goal to advance cancer research and treatment for all patients.”
The Caris Precision Oncology Alliance includes 69 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1,000,000 data points per patient.
Learn more about cancer research at Northside.
